The Evaluation of Ultra-Innovative Drugs: A Broader Perspective
Abstract
This article explores the application of economic valuation methods to justify a drug price, when the incremental cost-effectiveness ratio (ICER) exceeds the threshold.
Authors
Mark Nuijten Jan Vis